Cargando…

Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics

BACKGROUND: The approval of the first biosimilar in the United States has placed increased pressure on the FDA to provide guidance on the naming convention that will be assigned to current and future biosimilars. The release of the FDA draft guidance on nonproprietary naming of biosimilars in August...

Descripción completa

Detalles Bibliográficos
Autor principal: Tomaszewski, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398106/
https://www.ncbi.nlm.nih.gov/pubmed/27459654
http://dx.doi.org/10.18553/jmcp.2016.22.8.919

Ejemplares similares